Last $61.47 USD
Change Today -2.65 / -4.13%
Volume 1.0M
KITE On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

kite pharma inc (KITE) Snapshot

Open
$64.21
Previous Close
$64.12
Day High
$64.21
Day Low
$61.02
52 Week High
01/15/15 - $89.21
52 Week Low
07/16/14 - $21.00
Market Cap
2.6B
Average Volume 10 Days
881.2K
EPS TTM
--
Shares Outstanding
41.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KITE PHARMA INC (KITE)

kite pharma inc (KITE) Related Businessweek News

No Related Businessweek News Found

kite pharma inc (KITE) Details

Kite Pharma, Inc. operates a clinical-stage biopharmaceutical company which focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate includes KTE-C19, a chimeric antigen receptors-based engineered autologous cell therapy for the treatment of patients with relapsed/refractory diffuse large B cell lymphoma. The company is also developing T cell receptors-based therapies, which targets SSX2, NY-ESO-1, and MAGE antigens in various cancers. The company has strategic research collaboration and license agreement with Amgen Inc. to advance the application of novel chimeric antigen receptor T cell therapies; and collaboration agreement with the Surgery Branch of the National Cancer Institute. Kite Pharma, Inc. was founded in 2009 and is headquartered in Santa Monica, California.

36 Employees
Last Reported Date: 12/12/14
Founded in 2009

kite pharma inc (KITE) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $16.7K
Vice President of Translation Medicine
Total Annual Compensation: $325.0K
Consultant
Total Annual Compensation: $210.9K
Compensation as of Fiscal Year 2013.

kite pharma inc (KITE) Key Developments

Kite Pharma, Inc. Amends Cooperative Research and Development Agreement with National Cancer Institute

Kite Pharma, Inc. announced that the company has amended its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). The amendment will encompass emerging areas of research in the immune response to tumor neo-antigens, truly tumor-specific antigens generated as tumors accumulate genetic mutations. In addition, new T cell receptor (TCR) and new chimeric antigen receptor (CAR) product candidates targeting solid tumors have been added to the collaboration. The amendment broadens Kite's ongoing research collaboration with the Surgery Branch at the NCI, led by Steven A. Rosenberg, M.D., Ph.D. and provides additional product candidates for Kite's growing pipeline. Under Kite's amended agreement with the NCI, the additional programs will encompass: Methods of rapidly identifying and developing TCR product candidates targeted against neo-antigens; Optimizing new methods to manufacture this new class of individualized therapies; Developing additional TCR product candidates retrovirally engineered to target tumor antigens, including for the treatment of colorectal and lung cancers.

Kite Pharma, Inc. Enters into Lease Agreement for Commercial Manufacturing Facility in El Segundo, California

Kite Pharma, Inc. announced that it has entered into a lease agreement for a commercial manufacturing facility in El Segundo, California, which is adjacent to Los Angeles International Airport. Kite also recently secured a lease for a clinical manufacturing facility in Santa Monica, California. The two facilities will not only support the planned clinical trials of Kite's product candidates, but also will prepare Kite for the commercial launch and supply of its lead product candidate, KTE-C19, anticipated in 2017. The Santa Monica facility has approximately 18,000 square feet and will provide space for clinical manufacturing, research and development, and offices upon completion. In addition, Kite plans to continue to utilize its contract manufacturer to support clinical trials of eACT based product candidates. The El Segundo facility has approximately 44,500 square feet, and, under the lease agreement, Kite has an expansion option for an additional 17,000 square feet until July 1, 2017. Kite was represented in the negotiation of the lease by Andrew Riley and Jeff Pion of CBRE. Kite anticipates the El Segundo facility will be operational to support the planned commercial launch of KTE-C19 in 2017.

Kite Pharma, Inc. Announces New Appointments

Kite Pharma, Inc. announced the appointments of Salah D. Kivlighn, Ph.D., as Vice President, Marketing, and Anthony J. Polverino, Ph.D., as Vice President, Research. Dr. Kivlighn will play a critical role spearheading the Company's marketing strategy. He will report to Cynthia M. Butitta, Chief Financial Officer and Chief Operating Officer. Dr. Polverino will lead the research and development of various eACT™ candidates. He will report to Margo R. Roberts, Ph.D., Chief Scientific Officer. Dr. Kivlighn has more than twenty-five years of experience in the pharmaceutical and biotech industry. Most recently, he was a Global Product Development Team leader at Medimmune, spearheading programs in oncology and autoimmunity, and prior to this was Head of Global Strategic Marketing. Dr. Polverino has substantial background and expertise in the immunotherapy field. He joins Kite from Amgen, most recently serving as Executive Director Research, Therapeutic Innovation Unit, a role in which he made significant contributions to advancing multiple clinical programs, including immunotherapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KITE:US $61.47 USD -2.65

KITE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KITE.
View Industry Companies
 

Industry Analysis

KITE

Industry Average

Valuation KITE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 12.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KITE PHARMA INC, please visit www.kitepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.